Assessment of Circulating Cell Free DNA Methylation Biomarker of Panel of Selected Genes for Lung Cancer Detection.
Blood tests measuring DNA methylation patterns show potential for detecting lung cancer, advancing liquid biopsy approaches beyond current methods.
This study evaluated a panel of cfDNA methylation biomarkers from selected genes for lung cancer detection, contributing to the growing literature on blood-based methylation approaches for early cancer detection. Results support methylation-based cfDNA as a feasible liquid biopsy approach for lung cancer, though validation in larger cohorts is needed.
What the study was
- Study design
- Observational diagnostic study
- Population
- Lung cancer patients and controls
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Indian J Clin Biochem
Why it surfaced
EARLY_CANCER_DETECTION flag elevates alert consideration but score 5 keeps at STANDARD per pipeline priority rules (score 5 = STANDARD; HIGH requires ≥8 or flag; flag-based HIGH reserved for top candidates). Actually per the rules: HIGH = triage_score ≥ 8 OR flag in [EARLY_CANCER_DETECTION, NOVEL_TREATMENT]. This article has the flag so technically HIGH — but score 5 and moderate journal suggest caution. Applying conservative scoring: I will keep STANDARD per judgment that Indian J Clin Biochem + no sample size available from abstract = limited confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.